Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination Abbott and AstraZeneca confirmed they’ll advance the development of Abbott’s next-generation fenofibrate ABT-335 and AstraZeneca’s CRESTOR in a fixed-dose combination treatment into Stage III clinical trials. The single pill would target all three major bloodstream lipids – – LDL-C bad cholesterol, HDL-C great cholesterol, and triglycerides. ABT-335 is Abbott’s next-generation fenofibrate currently in late-stage clinical trials vardenafil hcl . Based on the significant progress manufactured in the ABT-335 and CRESTOR fixed-dose combination development program, the companies have decided to go forward with this fixed-dosage combination therapy jointly.
Visiogen’s Synchrony zoom lens allows Abbott Medical Optics to enter the developing accommodating IOL segment and enhances our high quality IOL portfolio that includes the Tecnis Multifocal lens, said Jim Mazzo, senior vice president, Abbott, and president, Abbott Medical Optics. Abbott entered the vision care segment following its February 2009 acquisition of Advanced Medical Optics. Abbott Medical Optics offers a range of cataract, refractive and corneal products designed to meet the needs of sufferers who suffer from a wide range of eyesight disorders and seek greater freedom from the restrictions of eyeglasses. This deal is subject to customary closing conditions and regulatory approvals and is likely to close in the fourth one fourth of 2009.